Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 4/2015

01.07.2015 | Clinical Investigation

Prognosis of patients with diabetic macular edema before Japanese approval of anti-vascular endothelial growth factor

verfasst von: Satoshi Serizawa, Kishiko Ohkoshi, Yuko Minowa, Osamu Takahashi

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To examine the prognosis of patients with diabetic macular edema (DME) before Japanese approval of antivascular endothelial growth factor (VEGF).

Methods

This retrospective study included 135 eyes of 115 patients who received treatments (photocoagulation, pharmacological treatments, vitrectomy) for DME between January 2003 and August 2012. The best-corrected visual acuity (BCVA) before and 1, 3, 6, 12, and 24 months after treatment was examined. BCVA was classified based on the decimal value of BCVA before treatment as good (BCVA > 0.7, BCVA = 0.7), moderate (BCVA > 0.7 but <0.2), or poor (BCVA < 0.2, BCVA = 0.2), and each prognosis of BCVA was investigated.

Results

Thirty-five (25.9 %) patients were classified with good BCVA, while 69 (51.1 %) had moderate and 31 (23.0 %) poor BCVA. Following 24 months of treatment, the averaged good BCVA maintained its value (0.0513 ± 0.0954 to 0.0773 ± 0.258). Similarly, the averaged moderate BCVA maintained its value (0.449 ± 0.169 to 0.441 ± 0.431), whereas the averaged poor BCVA significantly improved (1.070 ± 0.291 to 0.879 ± 0.361: p < 0.001). Specifically, the averaged BCVA of patients who initially received vitrectomy increased 0.380 logMAR after 24 months (0.859 ± 0.414 to 0.479 ± 0.549).

Conclusion

DME patients with good BCVA at the time of initial treatment generally maintained the averaged BCVA at 24 months, while patients with moderate BCVA did not significantly improve without a standard regimen of anti-VEGF therapy. However, the results indicate that early vitrectomy is a potential treatment option for DME patients with poor BCVA.
Literatur
1.
Zurück zum Zitat Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–806.CrossRef Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–806.CrossRef
2.
Zurück zum Zitat Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987;94:761–74.CrossRef Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 2. Ophthalmology. 1987;94:761–74.CrossRef
3.
Zurück zum Zitat Lewis H, Abram GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99:753–9.PubMedCrossRef Lewis H, Abram GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99:753–9.PubMedCrossRef
4.
Zurück zum Zitat Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol. 2001;132:369–77.PubMedCrossRef Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol. 2001;132:369–77.PubMedCrossRef
5.
Zurück zum Zitat Kumagai K, Furukawa M, Ogino N, Larson E, Iwaki M, Tachi N. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina. 2009;29:464–72.PubMedCrossRef Kumagai K, Furukawa M, Ogino N, Larson E, Iwaki M, Tachi N. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina. 2009;29:464–72.PubMedCrossRef
6.
Zurück zum Zitat Martidis A, Ducker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920–7.PubMedCrossRef Martidis A, Ducker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920–7.PubMedCrossRef
7.
Zurück zum Zitat Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245–51.PubMedCrossRef Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009;127:245–51.PubMedCrossRef
8.
Zurück zum Zitat Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.PubMedCrossRef Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.PubMedCrossRef
9.
Zurück zum Zitat Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol. 2013;131:139–45.PubMedCrossRef Do DV, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol. 2013;131:139–45.PubMedCrossRef
10.
Zurück zum Zitat Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013–22.PubMedCrossRef Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013–22.PubMedCrossRef
11.
Zurück zum Zitat Nguyen QD, Shah SM, Heir JS, Boyer DS, Patel S, Feiner L, et al. Primary End Point (six months) Results of the Ranibizumab for Edema of the macula in diabetes (READ-2) study. Ophthalmology. 2009;116(2175–81):e1. Nguyen QD, Shah SM, Heir JS, Boyer DS, Patel S, Feiner L, et al. Primary End Point (six months) Results of the Ranibizumab for Edema of the macula in diabetes (READ-2) study. Ophthalmology. 2009;116(2175–81):e1.
12.
Zurück zum Zitat Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405.PubMedCentralPubMedCrossRef Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399–405.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Research Diabetic Retinopathy Clinical, Network Elman ML, Qin H, Aillo LP, Beck RW, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119:2312–8.CrossRef Research Diabetic Retinopathy Clinical, Network Elman ML, Qin H, Aillo LP, Beck RW, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119:2312–8.CrossRef
14.
Zurück zum Zitat Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127:688–93.PubMedCrossRef Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127:688–93.PubMedCrossRef
15.
Zurück zum Zitat Abedi G, Patal P, Doros G, Subramanian ML. Transitioning from stratus OCT to cirrus OCT: a comparison and a proposed equation to convert central subfield macular thickness measurements in healthy subjects. Graefes Arch Clin Exp Ophthalmol. 2011;249:1353–7.PubMedCrossRef Abedi G, Patal P, Doros G, Subramanian ML. Transitioning from stratus OCT to cirrus OCT: a comparison and a proposed equation to convert central subfield macular thickness measurements in healthy subjects. Graefes Arch Clin Exp Ophthalmol. 2011;249:1353–7.PubMedCrossRef
16.
Zurück zum Zitat Ohkoshi K, Yamaguchi T. Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients. Am J Ophthalmol. 2010;149:133–9.PubMedCrossRef Ohkoshi K, Yamaguchi T. Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients. Am J Ophthalmol. 2010;149:133–9.PubMedCrossRef
17.
Zurück zum Zitat Othman IS, Eissa SA, Kotb MS, Sadek SH. Subthreshold diode-laser micropulse photocoagulation as a primary and secondary line of treatment in management of diabetic macular edema. Clin Ophthalmol. 2014;8:653–9.PubMedCentralPubMed Othman IS, Eissa SA, Kotb MS, Sadek SH. Subthreshold diode-laser micropulse photocoagulation as a primary and secondary line of treatment in management of diabetic macular edema. Clin Ophthalmol. 2014;8:653–9.PubMedCentralPubMed
Metadaten
Titel
Prognosis of patients with diabetic macular edema before Japanese approval of anti-vascular endothelial growth factor
verfasst von
Satoshi Serizawa
Kishiko Ohkoshi
Yuko Minowa
Osamu Takahashi
Publikationsdatum
01.07.2015
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 4/2015
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-015-0384-2

Weitere Artikel der Ausgabe 4/2015

Japanese Journal of Ophthalmology 4/2015 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.